Fresenius agrees to pay $250M to settle GranuFlo and NaturaLyte
Fresenius slips 1st Naturalyte bellwether trial
Fresenius Medical Care (NYSE:FMS) last week won the 1st bellwether trial in a series of product liability lawsuits brought over its GranuFlo and NaturaLyte dialysis drugs, after a Massachusetts jury found that the plaintiff’s estate failed to prove its …
Beshear sues nation’s largest kidney dialysis provider
Beshear claimed in the suit filed in Franklin Circuit Court that Fresenius, headquartered in Waltham, Mass., promoted its kidney dialysis product, GranuFlo, as safe despite clinical trials finding it harmful.
The lawsuit seeks to recover damages and …
Lawsuit claims DaVita hid harmful effects of dialysis solution that caused heart attacks
The lawsuit says that since at least 2004, DaVita used a dialysis solution called GranuFlo that caused complications including heart attacks and strokes.
On Nov. 4, 2011, an internal study by Fresenius Medical Care, the maker of GranuFlo, resulted in a …
$250 Million Settlement Reached in Granuflo Litigation
Fresenius Medical Care, one of the largest providers of dialysis products in the world, has agreed to set aside $250 million to settle more than 10,000 lawsuits filed by dialysis patients and family members.
The plaintiffs in those lawsuits allege use …
Fresenius pays $250M to settle GranuFlo/NaturaLyte lawsuits
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) agrees to pay $250M to resolve U.S. litigation related to its GranuFlo and NaturaLyte products.
Under the terms of the agreement, 97% of the plaintiffs must agree to the settlement by July to receive …
Please follow and like us: